Sun Pharma Advanced Research Company Share Price Target 2026: Stock Analysis, Share Price Today, Bull Case and Bear Case After Q1 FY27
- July 1, 2026
- Posted by: Neeraj Pandey
- Category: News
Sun Pharma Advanced Research Company Rs 196.79 (7 Oct 2026 close). 52-week range Rs 108.00 to Rs 289.00. Q1 FY27 consolidated loss Rs 20.78 cr; trailing EPS Rs 48.82 from a one-time voucher sale.
Quick Answer
The Sun Pharma Advanced Research Company share price target for 2026 is Rs 164 to Rs 213, which is between 17 percent below and 8 percent above the last close of Rs 196.79, with bull and bear cases of Rs 238 to Rs 287 and Rs 102 to Rs 144. Sun Pharma Advanced Research Company reported a Q1 FY27 consolidated net loss of Rs 20.78 crore against Rs 51.87 crore a year ago, after a one-time Rs 29.21 crore licence termination payment lifted revenue to Rs 39.92 crore. The trailing P/E of about 4 times comes from a one-time priority review voucher sale in Q4 FY26 that produced a Rs 1,761 crore profit, so it cannot be repeated, and the stock trades at 4.8 times book value. No brokerage price target was available on the sources we track as of 7 October 2026, so every range below is a Univest research scenario.
The Sun Pharma Advanced Research Company share price target for 2026 is Rs 164 to Rs 213 in the Univest base case, with the stock at Rs 196.79 at the 7 October 2026 close. That is 31.9 percent below its 52-week high of Rs 289.00 and 82.2 percent above its 52-week low of Rs 108.00, and the stock moved up 46.8 percent over the past year. Sun Pharma Advanced Research Company, or SPARC, is a clinical-stage pharma R&D company in the Sun Pharma group. Debt to equity is 0.42 and the company pays no dividend.
Three things changed since the last update: Q1 FY27 results on 10 August showed a narrower loss helped by a one-time licence payment, the board approved promoter reclassifications, and the stock fell about 32 percent from its Rs 289 July spike. This Sun Pharma Advanced Research Company stock analysis covers the Sun Pharma Advanced Research Company share price today, the Sun Pharma Advanced Research Company share price target for 2026, 2027 and 2030, the Q1 FY27 numbers, catalysts and risks, key price levels and a Sun Pharma Advanced Research Company buy or sell view.
Click Here – Get Free Investment Predictions
What Is the Sun Pharma Advanced Research Company Share Price Target for 2026?
The 2026 target for Sun Pharma Advanced Research Company shares is Rs 164 to Rs 213 in the Univest base case, which is -16.7% to +8.2% against the last close. The bull case is Rs 238 to Rs 287 and the bear case is Rs 102 to Rs 144. No brokerage price target was available on the sources we track as of 7 October 2026, so every range below is a Univest research scenario. Analyst consensus is used as a cross-check, not as the base.
Sun Pharma Advanced Research Company Share Price Target Scenarios: Bull Case, Base Case and Bear Case
| Scenario | FY28E Book Value | Target Multiple | Price Target (Rs) | Move vs Rs 196.79 |
|---|---|---|---|---|
| Bull Case | Rs 41 | 5.8x to 7x | 238 to 287 | +20.9% to +45.8% |
| Base Case | Rs 41 | 4x to 5.2x | 164 to 213 | -16.7% to +8.2% |
| Bear Case | Rs 41 | 2.5x to 3.5x | 102 to 144 | -48.2% to -26.8% |
SPARC has no recurring earnings, so a PE valuation does not apply. The ranges use price to book on a FY28 book value of Rs 41 per share, which compares with Rs 41.26 now. The stock trades at 4.8 times book, and the cases range from a de-rating to 2.5 to 3.5 times book to a re-rating to 5.8 to 7 times if a milestone adds value. The PE multiple of about 4 times reflects a one-time voucher sale and cannot be repeated, so the table uses price to book in place of an EPS estimate, and the book value is a Univest assumption, not company guidance. Those assumptions set the Sun Pharma Advanced Research Company share price target range around the current price.
Sun Pharma Advanced Research Company Company Overview and Share Price Today as of 7 October 2026
Sun Pharma Advanced Research Company share price today is Rs 196.79 on the NSE at the 7 October 2026 close, before the market opens on 8 October. The market capitalisation is Rs 6,413 crore, and the stock shows a PE of 4 times that reflects a one-time voucher sale, against an industry average of 37.8 times. The Univest base case Sun Pharma Advanced Research Company share price target of Rs 164 to Rs 213 is -16.7% to +8.2% from here. The table below sets out the key numbers behind the Sun Pharma Advanced Research Company share price target.
| Parameter | Value | Context |
|---|---|---|
| NSE Ticker | SPARC | BSE code 532872 |
| Sector | Clinical-stage pharma R&D | Per Univest sector classification |
| Last Close (NSE) | Rs 196.79 | 7 Oct 2026 close |
| 52-Week High | Rs 289.00 | CMP is 31.9% below |
| 52-Week Low | Rs 108.00 | CMP is 82.2% above |
| 1-Year Return | About +47% | Weekly close Rs 134.01 on 10 Oct 2025 to Rs 196.79 |
| Market Capitalisation | Rs 6,413 crore | Small cap pharma R&D company |
| Trailing P/E | About 4.05x (one-off income) | Industry P/E about 37.76x |
| P/B Ratio | About 4.79x | Book value Rs 41.26 per share |
| EPS (TTM) | Rs 48.82 | Trailing twelve months |
| Return on Equity | About 116.0% | Debt to equity 0.42 |
| Dividend Yield | Nil | No dividend |
| 12-Month Target (Base Case) | Rs 164 to Rs 213 | Univest base case |
| Bull Case | Rs 238 to Rs 287 | +20.9% to +45.8% |
| Bear Case | Rs 102 to Rs 144 | -48.2% to -26.8% |
How Did Sun Pharma Advanced Research Company Perform in Q1 FY27?
Sun Pharma Advanced Research Company reported a Q1 FY27 standalone net loss of Rs 20.98 crore against Rs 52.03 crore a year ago, and a consolidated net loss of Rs 20.78 crore against Rs 51.87 crore. Standalone revenue was Rs 39.92 crore, up from Rs 9.64 crore. Together these Q1 FY27 numbers anchor the Sun Pharma Advanced Research Company share price target.
| Metric | Q1 FY27 | Context |
|---|---|---|
| Standalone Revenue | Rs 39.92 crore | Against Rs 9.64 crore a year ago |
| Standalone Net Loss | Rs 20.98 crore | Against Rs 52.03 crore |
| Consolidated Net Loss | Rs 20.78 crore | Against Rs 51.87 crore |
| One-Time Licence Payment | Rs 29.21 crore | From a terminated CMS Bridging DMCC agreement |
| Q4 FY26 Profit | Rs 1,761 crore | One-time priority review voucher sale |
| EPS (Q1 FY27) | Rs -0.64 | Consolidated |
The revenue rise came from non-refundable consideration recognised after the mutual termination of a licensing agreement with CMS Bridging DMCC, not from product sales. The Q4 FY26 profit was the result of a one-time voucher sale, which is why the trailing P/E and ROE of 116 percent do not describe earning power. The FY27 outlook from management is the main input for these estimates. These numbers sit behind every range in the scenario table above, so they anchor the Sun Pharma Advanced Research Company share price target.
Why Is Sun Pharma Advanced Research Company Share Price Up 82 Percent From Its March Low?
Sun Pharma Advanced Research Company shares are about 82 percent above the Rs 108 low of the week of 23 March 2026 and up 47 percent in a year. The stock rose 21 percent in the week of 4 May and 28 percent in the week of 18 May on volume of 4.3 crore and 9 crore shares, around the Q4 FY26 results period that showed the one-time voucher sale profit.
It touched Rs 253 in the week of 15 June and spiked to Rs 289 in the week of 6 July on 3.1 crore shares, then fell about 32 percent to Rs 196.79 as the one-off gains faded. A Dec 2025 jump of 14 percent on 22.6 crore shares also has no confirmed cause. The Sun Pharma Advanced Research Company share price target scenarios below account for that move.
Key Catalysts for the Sun Pharma Advanced Research Company Share Price Target in 2026
4 catalysts matter most for the Sun Pharma Advanced Research Company share price target, and sector tailwinds in Clinical-stage pharma R&D are part of the case. Together they decide whether the base case is reached.
1. Voucher Sale Cash
A one-time priority review voucher sale produced Rs 1,761 crore of profit in Q4 FY26. It strengthened the balance sheet for further research. If it plays out, the Sun Pharma Advanced Research Company share price target moves toward the top of the base range.
2. Licensing Optionality
The company earns licence income when partners sign or end deals. A new licence would add revenue. Strength here would support the upper end of the Sun Pharma Advanced Research Company share price target.
3. Pipeline
SPARC develops its own drug candidates in the Sun Pharma group. A clinical milestone could re-rate the stock. Delivery on this point keeps the Sun Pharma Advanced Research Company share price target on track.
4. Cost Control
The quarterly loss narrowed to Rs 20.78 crore. Lower burn extends the cash runway. Better news here would lift the Sun Pharma Advanced Research Company share price target toward the bull case.
What Are the Key Risks to the Sun Pharma Advanced Research Company Share Price Target?
The main risks are no recurring profit, clinical failure, one-off income and a rich book multiple. Each can pull the Sun Pharma Advanced Research Company share price target lower.
No Recurring Profit
Outside one-off items the company loses money. Cash burn continues until a product earns revenue. If it materialises, the Sun Pharma Advanced Research Company share price target would slip toward the bear case.
Clinical Failure
Research can fail at any stage. A failed trial would cut the book value multiple. This is the main downside risk to the Sun Pharma Advanced Research Company share price target.
One-Off Income
Q4 FY26 and Q1 FY27 profit and revenue relied on one-time items. These cannot repeat on demand. A worsening here would cut the Sun Pharma Advanced Research Company share price target toward the low end of the range.
Book Multiple Reset
A bear case of Rs 41 book value at 2.5 times would put the price near Rs 103. Watch it closely, because it can pull the Sun Pharma Advanced Research Company share price target lower quickly.
Sun Pharma Advanced Research Company Stock Analysis: Support and Resistance Levels for the Share Price Target
Sun Pharma Advanced Research Company stock analysis on weekly charts shows a range of Rs 182 to Rs 212 since mid-September, with the stock in the middle.
The first support level is Rs 189.01 to Rs 190.20, the lows of the weeks of 28 September and 5 October. Below that, Rs 182 is the low of the week of 14 September and Rs 108 is the 52-week low.
The first resistance level is Rs 201.59, the high of the week of 5 October. Above that, Rs 208.65 to Rs 212 marks the highs of the weeks of 7, 28 and 21 September. These levels come from weekly price action, are not trade recommendations, and frame the near-term Sun Pharma Advanced Research Company share price target.
Sun Pharma Advanced Research Company Share Price Target 2026, 2027 and 2030: Short, Medium and Long Term
Short-Term Sun Pharma Advanced Research Company Share Price Target (3 to 6 Months)
In the near term the stock is likely to trade between Rs 189 and Rs 212. A close above Rs 212 would put Rs 220 in play, while a weekly close under Rs 189 would open Rs 182. Pipeline news and the Q2 FY27 results are the main triggers. This range anchors the near-term Sun Pharma Advanced Research Company share price target.
12-Month and 2027 Sun Pharma Advanced Research Company Share Price Target
The 12-month target price is Rs 164 to Rs 213, valued on 4 to 5.2 times FY28 book value of Rs 41. The range across scenarios runs from Rs 102 in the bear case to Rs 287 in the bull case.
Long-Term Sun Pharma Advanced Research Company Share Price Target for FY29 to 2030
For FY29 to 2030 the Univest scenario range is Rs 160 to Rs 240. This assumes book value of Rs 40 in FY29 and Rs 40 in FY30 and a multiple of 4 to 6 times. It needs a clinical or licensing milestone to add value, cash burn to stay contained and no further one-off dependence. This is the long-term Sun Pharma Advanced Research Company share price target in the Univest scenarios.
Bull Case and Bear Case for Sun Pharma Advanced Research Company Share Price Target
Bull Case Rs 238 to Rs 287
The bull case of Rs 238 to Rs 287 for the Sun Pharma Advanced Research Company share price target needs book value of Rs 41 and the market to pay 5.8 to 7 times for it. It is +20.9% to +45.8% from the last close.
Bear Case Rs 102 to Rs 144
The bear case of Rs 102 to Rs 144 for the Sun Pharma Advanced Research Company share price target equals 2.5 to 3.5 times FY28 book value of Rs 41 and sits near the Rs 108 low. It is -48.2% to -26.8% from the last close.
Is Sun Pharma Advanced Research Company a Good Buy at Rs 197? Sun Pharma Advanced Research Company Buy or Sell View
Whether Sun Pharma Advanced Research Company is a buy at Rs 196.79 depends on horizon and risk appetite. The base case sits between 17 percent below and 8 percent above the current price, the stock is 32 percent below its July spike, and the open question is whether the pipeline can create value. The Sun Pharma Advanced Research Company share price target range is the starting point for that decision.
Long-term holders may focus on the pipeline, cash burn and licensing news, and treat Rs 182 as the level to watch. Short-term traders may prefer to wait for a close above Rs 212. Check institutional holding in the September quarter filing for signs of accumulation or selling. Consult a SEBI-registered advisor before acting, since this Sun Pharma Advanced Research Company buy or sell view is educational.
How to Invest in Sun Pharma Advanced Research Company Shares
Step 1: Check the live price, valuation and the latest Sun Pharma Advanced Research Company share price target range on the Univest Screener.
Step 2: Open a demat and trading account with a SEBI-registered broker such as Univest before acting on any Sun Pharma Advanced Research Company share price target.
Step 3: Search for SPARC on the NSE or 532872 on the BSE in your trading app.
Step 4: Place a limit order near your planned entry and size the position so a fall to Rs 102 is bearable.
Step 5: Track pipeline updates, cash burn and Q2 FY27 results and set price alerts on the Univest App to follow any change in the Sun Pharma Advanced Research Company share price target.
Conclusion
Sun Pharma Advanced Research Company closed at Rs 196.79 against a Univest base case share price target of Rs 164 to Rs 213, a bull case of Rs 238 to Rs 287 and a bear case of Rs 102 to Rs 144. Q1 FY27 showed a narrower loss of Rs 20.78 crore helped by a one-time licence payment. The main risks are no recurring profit, clinical failure and one-off income.
The stock is 31.9 percent below its 52-week high, so the base case sits between 17 percent below and 8 percent above the current price. The triggers to watch are pipeline updates, cash burn and Q2 FY27 results and the Rs 189 and Rs 212 levels. Re-check the Sun Pharma Advanced Research Company share price target after each quarterly result. Investors with a long horizon and tolerance for volatility can track these triggers, while others may prefer to size positions carefully.
Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Sun Pharma Advanced Research Company Share Price Target 2026
What is the Sun Pharma Advanced Research Company share price target for 2026?
Ans. The Sun Pharma Advanced Research Company share price target for 2026 is Rs 164 to Rs 213 in the Univest base case, with a bull case of Rs 238 to Rs 287 and a bear case of Rs 102 to Rs 144. No brokerage target was available on the sources we track as of 7 October 2026, so these are Univest research scenarios. These are estimates and can change after the Q2 FY27 results.
What is the Sun Pharma Advanced Research Company share price target for 2027?
Ans. The Sun Pharma Advanced Research Company share price target for 2027 is Rs 164 to Rs 213 in the base case, valued on 4 to 5.2 times FY28 book value of Rs 41. The scenario range runs from Rs 102 to Rs 287.
Is Sun Pharma Advanced Research Company a good buy at Rs 196.79?
Ans. Whether Sun Pharma Advanced Research Company is a good buy at Rs 196.79 depends on your horizon, risk appetite and how you read the Sun Pharma Advanced Research Company share price target. The balance sheet is stronger after the voucher sale, but the core business loses money and the stock trades at 4.8 times book, so it is high risk. Consult a SEBI-registered advisor before investing.
What are the key risks to the Sun Pharma Advanced Research Company share price target?
Ans. The key risks to the Sun Pharma Advanced Research Company share price target are no recurring profit, clinical failure, one-off income and book multiple reset. Outside one-off items the company loses money. Cash burn continues until a product earns revenue.
What are the key catalysts for the Sun Pharma Advanced Research Company share price target?
Ans. The key catalysts for the Sun Pharma Advanced Research Company share price target are voucher sale cash, licensing optionality, pipeline and cost control. A one-time priority review voucher sale produced Rs 1,761 crore of profit in Q4 FY26. It strengthened the balance sheet for further research.
Where can I track Sun Pharma Advanced Research Company share price today and Sun Pharma Advanced Research Company share price target updates?
Ans. You can track the live Sun Pharma Advanced Research Company share price, results and any change to the Sun Pharma Advanced Research Company share price target on the Univest Screener and the Univest App. Download the Univest iOS App or Univest Android App for research from SEBI-registered analysts.
What are Sun Pharma Advanced Research Company’s 52-week high and low?
Ans. Sun Pharma Advanced Research Company’s 52-week high is Rs 289.00 and its 52-week low is Rs 108.00, based on weekly NSE data. At Rs 196.79 the stock is 31.9 percent below the high and 82.2 percent above the low. Both levels frame the Sun Pharma Advanced Research Company share price target.
How to buy Sun Pharma Advanced Research Company shares?
Ans. Open a demat account with a SEBI-registered broker such as Univest, search for SPARC on the NSE or 532872 on the BSE, and place a limit order near your entry price, using the Sun Pharma Advanced Research Company share price target range as a guide. Size the position so a fall to Rs 102 is bearable, and check the live price on the Univest Screener first.
